This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Citi Reaffirms Their Buy Rating on Becton Dickinson (BDX)

Tipranks - Tipranks - Thu Jul 9, 4:54AM CDT

In a report released on July 6, Joanne Wuensch from Citi reiterated a Buy rating on Becton Dickinson, with a price target of $198.00. The company’s shares closed yesterday at $155.54.

55% Off TipRanks

According to TipRanks, Wuensch is a 3-star analyst with an average return of 1.3% and a 52.74% success rate. Wuensch covers the Healthcare sector, focusing on stocks such as Integra Lifesciences, Abbott Laboratories, and Edwards Lifesciences.

In addition to Citi, Becton Dickinson also received a Buy from Evercore ISI’s Vijay Kumar in a report issued on July 6. However, on July 2, William Blair assigned a Hold rating to Becton Dickinson (NYSE: BDX).

See the top stocks recommended by analysts >>

Based on Becton Dickinson’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $4.71 billion and a GAAP net loss of $311 million. In comparison, last year the company earned a revenue of $5.27 billion and had a net profit of $308 million

Based on the recent corporate insider activity of 76 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BDX in relation to earlier this year. Last month, Thomas Polen, the COB, CEO & Pres of BDX sold 2,764.00 shares for a total of $404,511.40.

Read More on BDX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).